Successful Treatment of Scleromyxedema with Melphalan and Dexamethasone Followed by Thalidomide Maintenance Therapy

Xinxin Cao,Tao Wang,Yuehua Liu,Daobin Zhou,Jian Li

DOI: https://doi.org/10.1080/10428194.2016.1177183

2016-01-01

Abstract:Scleromyxedema (SM), the generalized papular and sclerodermoid form of lichen myxedematosus, is a fairly uncommon disease associated with monoclonal gammopathy and systemic manifestations.[1] It usually appears in middle and older age and affects men and women equally.[2,3] There are limited data regarding its pathogenesis, clinical course, and prognosis. Because of its rarity, there is no widely accepted consensus on the treatment of this disease. We have studied the clinical features and treatment outcomes of SM cases diagnosed at the Peking Union Medical College Hospital between January 2010 and December 2015. Diagnostic criteria were (i) generalized papular and sclerodermoid eruption; (ii) microscopic evidence of mucin deposition, fibroblast proliferation, and fibrosis; (iii) detection of monoclonal gammopathy; and (iv) absence of a concomitant thyroid disorder.[1] Clinical responses were evaluated according to the following parameters: (i) flattening of the papules; (ii) softening of skin induration; (iii) reduction of skin thickness; and (iv) improvement of systemic symptoms. Complete response (CR) was defined as the disappearance of symptoms and no detectable skin findings on examination. Partial response (PR) was defined as a decrease in skin changes and improvement in systemic symptoms.[4] Hematology response: CR was defined as negative immunofixation electrophoresis (IFE) of serum and urine. A very good partial response (VGPR) was defined as the serum and urine M components being detectable by IFE but not on electrophoresis or a 90% reduction in serum M component. PR was defined as 50% reduction of serum M-protein. Stable disease (SD) was defined as not meeting criteria for CR, VGPR, PR, or progressive disease. Progressive disease (PD) was defined as an increase of 25% from lowest response value in the serum M component. Five patients met the criteria for SM between January 2010 and December 2015, including three males and two females. The median age at diagnosis was 49 years (range 37–67 years). General characteristics of patients and treatments are outlined in Table 1. Median disease duration (from the first symptom to diagnosis) was 26 months (range 18–48 months). All five patients had the characteristic skin findings, which were generalized scleradermoid eruption studded with multiple, firm papules 1 to 3 mm in diameter involving the face, posterior ear, trunk, and limbs. All the patients had skin thickening and hyperpigmentation. Skin biopsy revealed dermal fibrosis with increased dermal mucin deposition. Only one patient (No. 2) had extracutaneous manifestations, namely, carpal tunnel syndrome that was demonstrated by electromyogram. None of the other four patients had any extracutaneous complaint, and the chest X-ray, transthoracic echocardiography, and pulmonary function tests were normal. The serum IFE showed IgGk monoclonal gammopathy in all five patients. The M protein of patient 1 could not be found by serum protein electrophoresis (SPE). The median M protein level determined by SPE of the other four patients was 2.9 g/L (range 1.3–6.5 g/L). One patient was excluded because no information about her treatment or follow-up was available. The other four patients were treated with 6 to 8 courses of a combination of melphalan and dexamethasone (MD) as induction therapy. MD was administered orally as